Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

UBXD3 Inhibitors

UBXD3 inhibitors are primarily focused on targeting the VCP/p97 complex, which is crucial for UBXD3's function in ciliogenesis and as a tethering factor in the intraflagellar transport complex B (IFT-B). The listed compounds, from NMS-873 to MG-132 [Z-Leu- Leu-Leu-CHO], are known to affect the activity of VCP/p97 or related pathways, thereby providing an indirect mechanism to modulate UBXD3 function. The indirect inhibition mechanism of these compounds involves primarily disrupting the normal function of VCP/p97. For instance, NMS-873 and CB-5083 are potent VCP/p97 inhibitors. By inhibiting VCP/p97, these compounds can disrupt its interaction with UBXD3, which is essential for UBXD3's role in ciliogenesis. Similarly, DBeQ, ML240, and ML241 are also VCP/p97 inhibitors and can affect UBXD3-mediated processes by hindering the normal functioning of VCP/p97.

Additionally, compounds like Eeyarestatin I and proteasome inhibitors like Bortezomib and MG-132 [Z-Leu- Leu-Leu-CHO] provide an indirect approach to influencing UBXD3's function. Eeyarestatin I inhibits ER-associated degradation, a process where VCP/p97 plays a significant role, and hence, could indirectly affect UBXD3. Proteasome inhibitors could impact the degradation pathways of proteins associated with UBXD3, influencing its functional dynamics. Moreover, compounds targeting the mTOR pathway, such as AZD8055, Rapamycin, and Torin 1, might also have implications in processes relevant to UBXD3's function. The mTOR pathway is integral to several cellular processes, including those related to ciliogenesis and protein homeostasis. These inhibitors, by modulating the activity of VCP/p97 and associated pathways, offer a strategic approach to indirectly influence UBXD3's function in the cell. Understanding the impact of these compounds on UBXD3-related processes can provide insights into the biological role of UBXD3, especially in the context of ciliogenesis and its interaction with the intraflagellar transport machinery. While direct inhibition of UBXD3 remains elusive, these compounds serve as valuable tools for exploring the broader network of cellular mechanisms in which UBXD3 is involved.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

NMS-873

1418013-75-8sc-478803
5 mg
$300.00
(0)

A VCP/p97 inhibitor, potentially disrupting the interaction with UBXD3 and affecting ciliogenesis.

DBeQ

177355-84-9sc-499943
10 mg
$330.00
1
(0)

A selective VCP/p97 ATPase inhibitor, potentially affecting UBXD3-mediated processes.

Eeyarestatin I

412960-54-4sc-358130B
sc-358130
sc-358130A
sc-358130C
sc-358130D
sc-358130E
5 mg
10 mg
25 mg
50 mg
100 mg
500 mg
$112.00
$199.00
$347.00
$683.00
$1336.00
$5722.00
12
(1)

Inhibits ER-associated degradation, a process where VCP/p97 is involved, potentially affecting UBXD3.

Harmine

442-51-3sc-202644
sc-202644A
sc-202644B
sc-202644C
sc-202644D
sc-202644E
sc-202644F
250 mg
500 mg
1 g
10 g
50 g
100 g
500 g
$52.00
$102.00
$124.00
$540.00
$1438.00
$2560.00
$11230.00
2
(2)

A DYRK1A inhibitor, possibly impacting pathways related to ciliogenesis and UBXD3 functions.

AZD8055

1009298-09-2sc-364424
sc-364424A
10 mg
50 mg
$160.00
$345.00
12
(2)

An mTOR inhibitor, potentially influencing pathways relevant to UBXD3's role in ciliogenesis.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Inhibits mTOR, which may impact ciliogenesis and processes involving UBXD3.

Torin 1

1222998-36-8sc-396760
10 mg
$240.00
7
(1)

A potent mTOR inhibitor, could affect cellular processes related to UBXD3's function.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

A proteasome inhibitor, potentially influencing pathways where UBXD3 is involved.

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$56.00
$260.00
$980.00
163
(3)

Inhibits proteasome, potentially impacting UBXD3-mediated protein degradation processes.